| TPF: Docetaxel, cisplatin, 5-flurouracil |
87 (16.4) |
| CDDP+PEM: Cisplatin, pemetrexed |
68 (12.8) |
| GC: Gemcitabine, cisplatin |
67 (12.6) |
| AP: Doxorubicin, cisplatin |
48 (9.0) |
| CDDP+VNR: Cisplatin, vinorelbine |
40 (7.5) |
| CDDP+S1+TRT: Oral S-1, cisplatin, thoracic radiation therapy |
37 (7.0) |
| CDDP+CPT-11: Cisplatin, irinotecan for cervical cancer |
31 (5.8) |
| DCF: Docetaxel, cisplatin, 5-flurouracil for gastric cancer |
31 (5.8) |
| CDDP+CPT-11: Cisplatin, irinotecan for lung cancer |
28 (5.3) |
| CDDP+S1: Oral S-1, cisplatin, |
24 (4.5) |
| CDDP+VP-16: Cisplatin, etoposide |
23 (4.3) |
| CDDP+DTX+TRT: Cisplatin, docetaxel, thoracic radiation therapy |
14 (2.6) |
| CDDP+5FU+Cet: Cisplatin, 5-flurouracil, cetuximab |
9 (1.7) |
| M-VAC: Methotrexate, vinblastine, doxorubicin, cisplatin |
7 (1.3) |
| CDDP+CPT-11: Cisplatin, irinotecan for gastric cancer |
6 (1.1) |
| SPT: Oral S-1, cisplatin, trastuzumab |
6 (1.1) |
| CDDP: Cisplatin |
4 (0.8) |
| CDDP+GEM: Gemcitabine, cisplatin |
2 (0.4) |
| Total |
532 (100) |
